Fuminori Yoshida remarks

Second founding: When we started selling our products

Break out of the venture shell and transform into a pharmaceutical company

To all those involved in SymBio Pharmaceuticals

With regard to domestic (Japan) sales of TREAKISYM, we have completed the transfer of sales from Eisai Co., Ltd., to which we have been consigning sales since its launch. We have deployed 62 of our highly specialized medical information representatives nationwide, and have established a nationwide sales system and an appropriate distribution and distribution system that can respond appropriately and accurately to the requests of medical professionals. At the same time, we established the Regulatory Affairs and Quality Assurance division to ensure the stable supply of products and further strengthen quality assurance.

This is also thanks to the many patients who have participated in clinical trials and the many doctors who have given us guidance. We would not have been able to do this without the understanding and cooperation of all of our employees, government officials, shareholders and many other venture capital and institutional investors who provided us with business funds, and all of our partner companies. I didn't get it. I would like to take this opportunity to express my sincere gratitude for the guidance and encouragement you have given us over the 15 years since our founding.

Since our founding in March 2005, we have consistently promoted the licensing, development, and commercialization of TREAKISYM. We are always keenly aware that "patients are waiting" in the future of our business TREAKISYM. We have been moving forward while cherishing The hurdles for bio-venture companies to record product sales are extremely high and difficult, but we value business continuity and believe that self-selling is the best option and will maximize shareholder value. In October 2018, we decided to switch to our own sales, and have been preparing for about two years.

Although it was a difficult start in the midst of the unexpected COVID-19 crisis, SymBio Pharmaceuticals has taken the first step towards its second founding today. This is entirely due to the support and assistance of many people who have contributed to our business, and we would like to share the joy of standing on a new starting line with everyone involved and the employees who have been involved in the implementation. I think. Aiming for dramatic growth and securing further profitability, SymBio Pharmaceuticals has achieved profitability, which was the first step in its second founding. We will continue to grow into a well-established specialty pharmaceutical company. In order to meet the expectations of all of you, we will continue to aim for even higher heights, and all of our officers and employees will work even harder together to work on our business. We ask for your continued support and cooperation.

December 10, 2020
Representative Director President and CEO
Fuminori Yoshida